Scholarlink

Background <p>Obesity is a growing global health crisis. Clinical trials have found high-dose semaglutide to be a promising medication for weight loss, but real-world effectiveness data is limited.</p> Objective <p>In this study we assessed weight loss outcomes with semaglutide treatment in patients with overweight or obesity who received care in a Veterans Affairs’ (VA) weight management clinic.</p> Design <p>We performed a retrospective review of patients at the Rocky Mountain Regional VA Medical Center who were started on semaglutide between January 1, 2021 and July 31, 2023. Patients included in the analysis were on the medication for the primary goal of weight loss regardless of their diabetes status, and those who were on semaglutide primarily for glycemic control were excluded.</p> Participants <p>The study included 201 veterans who were seen in the VA weight management clinic.</p> Main Measures <p>Our primary outcome of interest was mean percent weight loss at 12&#xa0;months. Changes in body mass index (BMI), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and hemoglobin A1c (HbA1c) were also analyzed.</p> Key Results <p>At 12&#xa0;months, the mean (SEM) total and percent weight loss were 11.5 (0.5) kg and 10.0 (0.6) % (p &lt; 0.001 from baseline), respectively. At 12&#xa0;months, total body weight loss of ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% was achieved in 74%, 50%, 24%, and 12% of patients, respectively. At 12&#xa0;months there was a reduction in SBP (SEM) of 3.4 (1.5) mmHg (p = 0.029), reduction in HbA1c of 0.32 (0.1) % (p &lt; .001), reduction in TG of 35.8 (11.8) mg/dL (p = .003), and reduction of LDL-C of 12.0 (4) mg/dL (p = 0.004).</p> Conclusions <p>Semaglutide treatment in a real-world VA weight management clinic setting resulted in significant weight loss and improvements in cardiovascular and metabolic outcomes, highlighting its effectiveness for managing obesity in veterans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Effectiveness of Semaglutide for Weight Loss in a Veterans Affairs’ Anti-Obesity Pharmacotherapy Clinic

  • 期刊论文

  • 发表日期：

    2025年11月13日

查看全文
  • Timothy McGinnis,
  • Molly McCallum,
  • Zhaoxing Pan,
  • Christina Cunningham,
  • David R. Saxon,
  • Elizabeth Thomas

摘要

Background

Obesity is a growing global health crisis. Clinical trials have found high-dose semaglutide to be a promising medication for weight loss, but real-world effectiveness data is limited.

Objective

In this study we assessed weight loss outcomes with semaglutide treatment in patients with overweight or obesity who received care in a Veterans Affairs’ (VA) weight management clinic.

Design

We performed a retrospective review of patients at the Rocky Mountain Regional VA Medical Center who were started on semaglutide between January 1, 2021 and July 31, 2023. Patients included in the analysis were on the medication for the primary goal of weight loss regardless of their diabetes status, and those who were on semaglutide primarily for glycemic control were excluded.

Participants

The study included 201 veterans who were seen in the VA weight management clinic.

Main Measures

Our primary outcome of interest was mean percent weight loss at 12 months. Changes in body mass index (BMI), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and hemoglobin A1c (HbA1c) were also analyzed.

Key Results

At 12 months, the mean (SEM) total and percent weight loss were 11.5 (0.5) kg and 10.0 (0.6) % (p < 0.001 from baseline), respectively. At 12 months, total body weight loss of ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% was achieved in 74%, 50%, 24%, and 12% of patients, respectively. At 12 months there was a reduction in SBP (SEM) of 3.4 (1.5) mmHg (p = 0.029), reduction in HbA1c of 0.32 (0.1) % (p < .001), reduction in TG of 35.8 (11.8) mg/dL (p = .003), and reduction of LDL-C of 12.0 (4) mg/dL (p = 0.004).

Conclusions

Semaglutide treatment in a real-world VA weight management clinic setting resulted in significant weight loss and improvements in cardiovascular and metabolic outcomes, highlighting its effectiveness for managing obesity in veterans.